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Introduction: In this study, we sought to address changes in blood lymphocyte subpopulations and labial salivary
gland (LSG) inflammation after belimumab treatment in patients with primary Sjögren’s syndrome (pSS) and to
identify predictors of response to treatment.
Methods: Sequential blood lymphocyte subsets and LSG biopsies were analysed between week 0 (W0) and W28 in
15 patients with pSS treated with belimumab. Systemic response to treatment was defined as a decrease in the
European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index score of ≥3 points at W28.
Results: After belimumab, we observed a decrease in blood B lymphocytes primarily involving CD27-negative/
immunoglobulin D–positive naïve B cells (p=0.008). Lymphocytic sialadenitis (focus score >1) that was present in 12
patients (80.0 %) before belimumab treatment became negative in 5 of them after treatment (p=0.03). The median
(interquartile range) LSG B-cell/T-cell ratio decreased from 0.58 (0.5–0.67) to 0.50 (0.5–0.5) (p=0.06). B-cell activating
factor (BAFF) staining was detected in 11 (78.6 %) of 14 patients before belimumab treatment compared with 7
(50.0 %) of 14 after belimumab therapy (p=0.10). The median percentage of BAFF-positive cells in foci significantly
decreased from 27.5 % (10–40) to 5 % (0–20) (p=0.03). A systemic response was achieved in six patients (40 %). The
only predictor of response was the presence of a low number of natural killer (NK) cells, both in blood (8.5 % [7–10]
vs 11 % [9–21]; p=0.04) and in LSG (20.6/mm3 [20.0–21.4] vs 30.0/mm3 [25.0–100.0], p=0.003). Serum BAFF levels did
not influence response to treatment.
Conclusions: Low blood and salivary NK cell numbers are associated with a better response to belimumab. This
suggests that two distinct subsets of pSS may exist: one with a predominant type I interferon (IFN)–BAFF–B-cell
axis, representing good responders to belimumab; and one with a predominant type II IFN–NK cell axis,
representing non-responders.
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Primary Sjögren’s syndrome (pSS) is a systemic auto-
immune disease that is characterised by mouth and eye
dryness as well as fatigue and pain. Systemic manifesta-
tions occur in 20–40 % of patients [1, 2]. B lymphocytes
play a crucial role in the pathogenesis of the disease in
their capacity to secrete autoantibodies and cytokines or
to present autoantigens.
Increased expression of the cytokine B-cell activating
factor (BAFF), also called B-lymphocyte stimulator [3], is
involved in the pathogenic mechanism of B-cell activa-
tion. BAFF plays a crucial role in B-cell maturation,
plasma cell survival, antibody response promotion and
immunoglobulin (Ig) class-switching recombination
[3, 4]. Its involvement in the pathogenesis of autoimmune
diseases and lymphomagenesis is demonstrated by
BAFF-transgenic mice that have autoimmune diseases
mimicking systemic lupus erythematosus (SLE) and pSS
and a rate of B-cell lymphoma twice that of control mice
[4]. Patients with SLE and pSS have elevated serum
levels of BAFF [5, 6], and serum levels of BAFF correlate
with autoantibody levels [6–8] and have been found to
be associated with pSS-associated lymphoproliferative
complications [9, 10].
Therefore, targeting B-cell activation and BAFF in the
setting of pSS seems appealing. Belimumab is the first
marketed anti-BAFF monoclonal antibody. It was recently
approved for treatment of SLE on the basis of two phase
III studies that showed positive results [11, 12]. Because
pathophysiological studies also suggested an involvement
of BAFF in the pathogenesis of pSS, we conducted the first
open-label proof-of-concept study to evaluate the efficacy
and safety of belimumab in pSS and found promising clin-
ical results, including a decrease in disease activity as
assessed using the European League Against Rheumatism
Sjögren’s Syndrome Disease Activity Index (ESSDAI) and
in patients’ symptoms as assessed using the European
League Against Rheumatism Sjögren’s Syndrome Patient
Reported Index (ESSPRI).
As a part of the present trial, we addressed the
changes in labial salivary gland (LSG) inflammation and
serum lymphocyte pattern after belimumab therapy and
identified predictors of response to treatment. We tried
to find patient patterns corresponding to probable in-
volved pathogenic pathways to make a first step toward
personalised medicine in this polymorphic disease.
Methods
Patients
The Efficacy and Safety of Belimumab in Subjects with
Primary Sjögren’s Syndrome (BELISS) trial included pa-
tients in two identical studies conducted at the same time
in two European centres, one in Paris, France, and one
in Udine, Italy (ClinicalTrials.gov registration numbersNCT01160666 and NCT01008982). Patients included ful-
filled the American-European Consensus Group criteria
for pSS [13], were positive for anti-Sjögren’s syndrome
antigen A or anti–Sjögren’s syndrome antigen B anti-
bodies and had, at the time of inclusion, at least one of the
following three characteristics: systemic complications or
persistent salivary gland enlargement, early disease (≤5
years from the beginning of symptoms) and/or presence
of at least one biomarker of B-cell activation (increase in
IgG level or free light chains or β2-microglobulinemia, de-
crease in complement component 4 [C4] level, presence
of cryoglobulinemia or monoclonal component). Other in-
clusion and exclusion criteria are reported elsewhere [14].
The patients received belimumab 10 mg/kg at week 0
(W0), W2 and W4 and then every 4 weeks to W24. Pa-
tients who responded to treatment at W28 were contin-
ued with belimumab monthly through W48, with a final
evaluation scheduled at W52 (4 weeks after the last dose).
The present study is part of the BELISS trial and in-
cluded analysis of changes in histological and serum
lymphocyte patterns between W0 and W28 in the 15 pa-
tients at the French centre.
Definitions of response to treatment
Response to treatment was defined at W28 according to
the composite primary endpoint, defined as follows: im-
provement in two of the following five parameters at
W28: ≥30 % reduction in dryness score on a visual
analogue scale (VAS), ≥30 % reduction in fatigue score
on a VAS, ≥30 % reduction in musculoskeletal pain score
on a VAS, ≥30 % reduction in systemic activity score on
a VAS assessed by the physician, and/or ≥25 % reduction
in serum levels of any of several B-cell activation bio-
markers (free light chains of Ig, β2-microglobulin, mono-
clonal component, cryoglobulin, IgG) or ≥25 % increase
in C4 level.
Systemic response was also assessed at W28 and was
defined as a decrease of ≥3 points in ESSDAI score [15]
in accordance with its minimal clinically important im-
provement [16]. Analyses of factors associated with re-
sponse to treatment were based primarily on systemic
response, which we considered the most robust way to
define relevant improvement.
BAFF assessment
BAFF was measured at baseline, before the first beli-
mumab dose, using an enzyme-linked immunosorbent
assay (Quantikine kit; R&D Systems, Minneapolis, MN,
USA).
Flow cytometry
Subtype lymphocyte counts for T, B and natural killer
(NK) cells were obtained by flow cytometry at W0, W4,
W12 and W28. The results are expressed in absolute
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blood sample of 200 μl was used for phenotyping subsets
of CD19+ with the following antibodies CD19 peridinin-
chlorophyll protein (PerCP, clone 4GT, catalogue num-
ber 345778; BD Biosciences, San Jose, CA, USA), IgD
fluorescein isothiocyanate (catalogue number H15501;
Invitrogen, Carlsbad, CA, USA) and CD27 allophycocyanin
(clone L128, catalogue number 337169; BD Biosciences).
After staining, the blood sample was fixed (Lyse/fix solu-
tion; BD Biosciences) and cells were acquired on a BD
FACSCalibur flow cytometer (BD Biosciences).
Among B cells, the following subtypes were analysed:
naïve (CD27−IgD+) B cells, memory (CD27+) B cells and
their subtypes (switched [CD27+IgD−] and unswitched
[CD27+IgD+]).
Histological assessment
Minor LSG biopsy samples were obtained at W0 and
W28. Samples of LSGs were fixed in alcohol, acetic acid
and formaldehyde solution and embedded in paraffin
wax for histological study. All samples were analysed by
the same pathologist (TL).
The following parameters were analysed: the focus
score, the B-cell/T-cell ratio in the foci, BAFF expression
in the foci and the NK infiltrate inside and outside the
foci. The focus score was measured after haematoxylin
eosin staining and was expressed as the number of foci
(50 lymphocytes) per 4 mm2. The focus score was con-
sidered abnormal if it was ≥1. B cells and T cells were
identified after CD20 (clone L26; DakoCytomation,
Glostrup, Denmark) and CD3 (clone F.7.2.38; DakoCyto-
mation) staining, respectively. The B-cell/T-cell ratio
was estimated in foci and expressed as the proportion of
B cells to T cells. BAFF expression was measured after
incubation with a rat anti-human BAFF antibody called
Buffy-2 (Enzo Life Sciences, Villeurbanne, France) and
expressed as the proportion of BAFF-expressing cells in-
side the foci, regardless to their origin (B or T cells). NK
cell infiltration was analysed after incubation with mouse
anti-human NKP46/NCR1 antibody (R&D Systems) in-
side and around the foci and was expressed as the num-
ber of NK cells per square millimetre as previously
described [17].
Ethics
The study protocol was approved by the French ethics
committee protection of humans in biomedical research
and the French agency for the safety of medicine and
health products. The study was conducted according to
the current regulations of the International Conference
on Harmonisation guidelines and the principles of the
Declaration of Helsinki. All patients provided written in-
formed consent before participating in any protocol-
specific procedures.Statistical analyses
Categorical variables are described with numbers (per-
centages). Quantitative variables are described with the
median (interquartile range).
To analyse changes between W0 and W28, values
were compared using Wilcoxon’s signed-rank test for
quantitative variables and McNemar’s test for categorical
variables.
To identify predictive factors of response to treatment,
baseline lymphocyte counts and histological parameters
were compared between responders and non-responders,
using a Kruskal-Wallis test for quantitative variables and
χ2 or Fisher’s exact test for categorical variables.
For all statistical analyses, a p value <0.05 was consid-
ered statistically significant. Data analysis was carried




All 15 patients were women. Their median age was 44
(36.5–63.5) years. Their median disease duration was 1
(0.5–6.5) year, and their median duration of symptoms
was 6.5 (4–12.5) years. Their characteristics are reported
in Table 1.
Among the 15 patients, 8 had salivary gland swelling at
the time of inclusion and 11 had other systemic complica-
tions, such as articular involvement (n=6), pulmonary in-
volvement (n=2), muscular involvement (n=1), peripheral
neuropathy (n=1), renal tubular acidosis (n=1) and auto-
immune thrombocytopenia (n=1).
Belimumab induced incomplete B-cell depletion mainly
linked to a dramatic decrease of naïve B cells
The available T, B and NK cell fluorescence-activated
cell-sorting analysis data allowed the evaluation of 13
patients at baseline and comparisons between W0 and
W28 in 11 patients. Regarding B-cell subtypes, data were
available at baseline for nine patients and for compari-
son between W0 and W28 for eight patients.
After belimumab treatment, the median total lympho-
cyte count (1346 [895–2069] at W0 vs 1471 [905–1847]
at W28; n=11), T cell count (902 [689–1655] at W0 vs
1152 [697–1367] at W28; n=11), CD4 (690 [471–890] at
W0 vs 724 [438–923] at W28; n=11) or CD8 T cells
(336 [135–541] at W0 vs 388 [185–544] at W28; n=11)
did not change significantly (Fig. 1a).
By contrast, there was a significant increase in the num-
ber of NK cells (145 [104–179] at W0 vs 184 [109–273] at
W28, n=11; p=0.032) (Fig. 1c). This number did not differ
according to the presence of systemic complications or
glandular involvement.
Conversely, we found a decrease in B lymphocytes
(CD19+). This decrease was observed as soon as W4
Table 1 Baseline characteristics of patients
All patients (N = 15)
Age, yr, median [IQR] 44 [36.5–63.5]
Female sex (%) 15 (100.0 %)
Disease duration, yr, median [IQR] 1 [0.5–6.5]
Whole unstimulated salivary flow (<0.1 ml/min) 12 (80 %)
Schirmer’s test ≤5 mm 10 (66.7 %)
Focus score ≥1 12 (80 %)
Baseline focus score, median [IQR] 1.6 [1–2.4]
Anti-SSA antibodies 14 (93.3 %)
Anti-SSB antibodies 10 (66.7 %)
Current background medication
Corticosteroids 4 (26.7 %)
Hydroxychloroquine 5 (33.3 %)
Methotrexate 0 (0 %)
Reason for inclusion
Systemic complications 11 (73.3 %)
Recent-onset disease 4 (26.7 %)
Increase in B-cell biomarker values 11 (73.3 %)
ESSDAI score (0–123), median [IQR] 7 [3–11]
ESSPRI score (0–10), median [IQR] 6.33 [6–7.33]
Anti-SSA anti-Sjögren’s syndrome antigen A antibodies, anti-SSB anti-Sjögren’s
syndrome antigen B antibodies, ESSDAI European League Against Rheumatism
Sjögren’s Syndrome Disease Activity Index, ESSPRI European League Against
Rheumatism Sjögren’s Syndrome Patient Reported Index, IQR Interquartile range
Fig. 1 Changes in T, B and natural killer (NK) cell counts and B-cell subtype
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and persisted during the whole treatment duration
(189 [31–296] W0 vs 81 [23–103] to W28, n=11;
p=0.01) (Fig. 1b).
This decrease primarily involved CD27−IgD+ naïve B
cells (151 [24–186] at W0 vs 10 [6–40] at W28, n=9;
p=0.008). There was no significant change in the total
number of CD27+ memory B cells (39.5 [10.1–53.2] at W0
vs 47.7 [19.1–64.9] at W28, n=9; p=0.074) or CD27+IgD+
unswitched memory B cells (8.8 [3.4–28.9] at W0 vs 15.7
[6.6–28.8] at W28, n=9; p=0.36), but there was a slight in-
crease in the number of CD27+IgD− switched memory B
cells at W28 (19.6 [6.7–30.3] at W0 vs 35.8 [12.5–38.2] at
W28; p=0.019) (Fig. 2).
Belimumab therapy induces decrease of BAFF expression
and B-cell/T-cell ratio in salivary glands
Minor LSG samples were obtained for all 15 patients at
both W0 and W28. All samples were analysed for esti-
mating focus and Chisholm scores, but only data of 14
patients were analysed for specific staining Fig. 3.
At inclusion, lymphocytic sialadenitis with a focus
score >1 was observed in 12 (80 %) of 15 patients, 5 of
whom had a negative test at W28 (p=0.03). Overall, the
median focus score decreased from 1.6 (1–2.4) to 0.5
(0–3) (p=0.39) and Chisholm score decreased from 4
(3–4) to 2 (1–4) (p=0.007).
The median B-cell/T-cell ratio decreased from 0.58
(0.5–0.67) to 0.50 (0.5–0.5) (p=0.06). The presence of
BAFF staining was detected in 11 (78.6 %) of 14 patients
before belimumab treatment and in only 7 (50.0 %) ofs after belimumab therapy. *p<0.05. W week
Fig. 2 Changes in natural killer (NK) cell count and proportion in
responders and non-responders. Number (upper plot) and percentage
(lower plot) of NK cells in responders and non-responders are
shown. *p<0.05
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percentage of BAFF-positive cells in foci significantly
decreased from 27.5 % (10–40) to 5 % (0–20) after beli-
mumab therapy (p=0.03). NKp46 staining revealed that
NK cell infiltration was located predominantly in inter-
stitia rather than in foci (24.7 [21.4–38.9] vs 8.2 NKp46+
cells/mm2 [4.2–10.0]; p=0.0003) and did not change
after belimumab treatment. Of note, we observed a cor-
relation, also found in one of our previous works, be-
tween the grading of focus score and the number of
NKp46+ cells outside the inflammatory foci (r2=0.425;
p<0.0001).
Low numbers of blood and salivary natural killer cells are
associated with a better response to belimumab
At W28, 6 (40 %) of the 15 patients were responders ac-
cording to the systemic definition (ESSDAI decrease of
≥3 points) and 7 (53 %) achieved the composite primary
endpoint, including the 6 systemic responders, showing
a high concordance between these 2 criteria. The follow-
ing analyses were based on systemic response.
Among the initial lymphocyte subpopulations, the only
parameters associated with systemic response to beli-
mumab were the percentage and number of NK cells
(8.5 % [7–10] in responders vs 11 % [9–21] in non-
responders, p=0.04; and 131 [104–145] in responders vs
179 cells/mm3 [168–210] in non-responders, p=0.06).
This was further confirmed at W12 (p=0.02) and W28(p=0.04), when lower NK cell counts were observed in
responders than in non-responders.
Also, change in NK cell absolute counts between W0
and W28 significantly differed between responders and
non-responders. Even if they started with a higher num-
ber of NK cells, non-responder patients showed a fur-
ther increase of NK cells compared with relative stability
in responders (+108 NK/mm3 [67–118] vs −23/mm3
[−26, +56]; p=0.017).
Neither baseline total nor B-cell subset cell counts,
nor their variations with treatment, were associated with
response to belimumab. Baseline serum BAFF levels also
did not differ between responders and non-responders
(790.3 pg/ml [692.1–927.4] vs 885.0 pg/ml [721.9–
1100.5]; p=0.79).
Regarding histological findings, the only parameter as-
sociated with systemic response to belimumab was the
importance of NK infiltrate in the periphery of the foci,
which was lower in responders than in non-responders
(median number of NK cells 20.6 [20.0–21.4] vs 30
NKp46+ cells/mm2 [25.0–100.0]; p=0.003).
Neither the percentage of BAFF-positive cells nor B-
cell/T-cell ratio was associated with the response to
belimumab.
Discussion
In the present study, we assessed blood and LSG
lymphocyte patterns before and after belimumab treat-
ment in patients with pSS. Belimumab treatment was as-
sociated with significant and early incomplete B-cell
depletion in peripheral blood involving the CD27−IgD+
naïve B-cell subset. Analyses of LSG biopsies demon-
strated a decrease in lymphocytic infiltration as assessed
by focus and Chisholm scores. A significant decrease in
the percentage of BAFF-positive cells within the foci was
also observed. The only predictor of response to beli-
mumab was a low count of blood and salivary NK cells.
Our study has two main limitations. First, it is an open
study with no control arm for comparison. Second, the
number of patients is small. Nevertheless, even in a
small group of patients, we found interesting, significant
results that reinforce their robustness and demonstrate
that studying a small, well-phenotyped group of patients
can be very informative.
The findings of the peripheral blood mononuclear cells
are in line with what is known about the effect of beli-
mumab therapy in patients with SLE. It is now estab-
lished that belimumab leads to a decrease in naïve B
cells and to stability or an early increase in memory B
cells [18, 19]. We confirmed this interesting observation
of an increase in memory B cells after belimumab treat-
ment. We hypothesised that the magnitude of this in-
crease in blood could reflect the importance of memory
B-cell infiltration in the tissue as previously described
Fig. 3 Changes in histological pattern of salivary glands after belimumab therapy. Regression of lymphocytic infiltration after belimumab therapy
(a before and b after; hematein-eosin-saffron stain; original magnification, ×125), major decrease of B-cell activating factor expression (c before
and d after; Buffy-2 immunohistochemical stain, original magnification, ×320.), dramatic decrease of B-cell infiltration (e before and f after; CD20
immunohistochemical stain; original magnification, ×250), with slight decrease or stability of T-cell infiltration (g before and h after; CD3
immunohistochemical stain; original magnification, ×250), resulting in a trend for a decrease in B-cell/T-cell ratio
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X-C motif ) ligand 13 has been shown to be necessary
for attracting memory B cells within germinal centres
[21]. However, with the limitation of a small number of
patients, we did not find any correlation between the
magnitude of this increase and the response to treat-
ment. To our knowledge, the monitoring of blood NK
cells has not been studied in SLE. In this study, wefound an effect of belimumab on NK cells whose abso-
lute count increased with treatment.
We demonstrate for the first time that belimumab may
induce changes in LSG infiltrate: decreases of lymphocytic
infiltrate, Chisholm score and BAFF-expressing cells in
the foci as well as a trend for a decreased B-cell/T-cell ra-
tio. The decrease of BAFF-expressing cells is of particular
interest but must be interpreted cautiously. It has been
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by monocytes and/or macrophages and dendritic cells
but also by T and B cells and by salivary epithelial
cells [22, 23]. However, the lowest number of BAFF-
expressing cells could be only the consequence of the
decrease of B cells expressing the BAFF receptor, with
BAFF passively bound on its receptor and detectable
by the anti-BAFF antibody.
The most interesting finding of the study is that, com-
pared with non-responders, patients who responded to
belimumab had a lower baseline number of NK cells,
both in blood and in LSG at the periphery of the foci.
We have previously shown that NK cells were present
mainly in the salivary glands in this location and could
play a role in pSS [17]. We have hypothesised that these
NK cells could participate in the increased interferon
(IFN)-γ expression seen in a subset of patients with pSS.
Indeed, the IFN signature observed in this disease may
be divided in patients harbouring a restricted type I sig-
nature, a restricted type II signature or both [24]. On the
one hand, type I IFN and B-cell activation could be
linked, as supported by studies showing that IFN-α can
induce BAFF [23, 25–27] and association between the
type I IFN signature and B-cell biomarkers [28]. On the
other hand, recent studies have highlighted the role of
the interleukin-12–IFN-γ axis in pSS pathogenesis [29].
Therefore, patients with a high baseline number of NK
cells in the blood or in the glands might correspond to
this second subset of patients having a high type II IFN
signature, suggesting a disease not predominantly driven
by B cells and thus less responsive to belimumab. Con-
versely, patients with low blood NK cell count or salivary
gland infiltration might be more dependent on the type I
IFN–B cell axis and may be good candidates for B-cell–
targeted therapy.
Interestingly, the lower NK cell count observed in
responders compared with non-responders persisted
throughout the study at W12 and W28, suggesting
that this difference in NK cell numbers might really be
the mirror of two types of pathogenesis in patients
with pSS.
Conclusions
We found very interesting results suggesting an effect of
belimumab on the glandular lymphoid infiltrate. One of
the main results is the identification of the NK cells as
an interesting predictive factor of the efficacy of beli-
mumab, suggesting that two types of disease can be
hypothesised in patients with pSS, the first one being
NK cell– and type II IFN–driven and not responsive to
B-cell–targeted therapy and the other being more B-
cell–driven and more responsive to belimumab therapy.
If the effectiveness of belimumab is confirmed in pa-
tients with pSS in randomised controlled studies, ourfindings could represent a first step toward personalised
medicine for patients with pSS.
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